A 940-patient real-world study confirms alectinib outperforms crizotinib in ALK-positive NSCLC, mirroring results from the ...
A third CRL was issued for rivoceranib plus camrelizumab in first-line unresectable/metastatic HCC, driven by cGMP ...
Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for ...
Bispecific antibodies have emerged as a transformative class of therapies in multiple myeloma and beyond, but the need for ...
In this interview with Targeted Oncology managing editor Sabrina Serani, Estelamari Rodriguez, MD, MPH, hematologist-oncologist at Sylvester Comprehensive Cancer Center, discusses ...
The first clinical case presents a 58-year-old female never-smoker with persistent cough, mild dyspnea, and new right-sided ...
CMS would set 340B drug payment at ASP–33.4%, lowering Medicare and beneficiary drug outlays while redistributing equivalent ...
The panel discusses the full multidisciplinary team required to optimize outcomes for patients with ROS1-positive advanced ...
SER-155 is an oral live biotherapeutic being investigated to treat disruptive conditions of the gastrointestinal tract. In a ...
Pettit, MD, and participants discussed second-line considerations in high-risk polycythemia after hydroxyurea failure.
FDA NDA acceptance for varegacestat positions it as a potential second oral targeted option for progressing desmoid tumors, ...
The T-cell immunotherapy Orca-T has gained FDA approval in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results